Coronavirus disease (COVID-19). a confirmed diagnosis of the 2019 novel coronavirus disease (COVID-19) as documented by the provider, documentation of a positive COVID-19 test result, or a presumptive positive COVID-19 test result.
Conditions
Interventions
Intervention 1: Intervention group: This group will be prescribed with Fluoxetine capsules for 28 days, with 10 milligram for the first 4 days followed by 20 milligram for the rest of the 4 week perio
Sponsors
Mazandaran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
16 Years to 65 Years
Inclusion criteria
Inclusion criteria: Patient's informed consent to participation in the study Speaking persian Established diagnosis of Covid-19 by a positive PCR or typical signs of the infection in lung ct scan Absence of depression, anxiety or other psychiatric disorders Absence of mental retardation Negative history of using psychotropic medication in the past 8 weeks No history of hepatic, renal or cardiac disorders BMI<30 Negative history of cigarette or other substance use Admission in non-ICU wards at the beginning of the intervention Absence of melatonin in the therapeutic regimen of the patient Fixed therapeutic regimen Not being pregnant at the time of admission
Exclusion criteria
Exclusion criteria: Suffering from the critical form of covid-19 Occurance of drug allergy or severe adverse effects of fluoxetine Necessity of changing the therapeutic regimen Inability in taking oral medications A score of 8 and above in any of HADS components
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Number of days of hospitalization. Timepoint: Daily from admission. Method of measurement: Number of days of hospital stay until patient's discharge.;Rate of need for intubation. Timepoint: Daily from admission. Method of measurement: Ratio of intubated patients to all of the patients in both intervention and placebo groups.;Mortality rate. Timepoint: Daily during hospitalization. Method of measurement: Ratio of deceased patients to the total number of patients admitted to the study. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public Contactfaranak sedighi tonekaboni
Iran University of Medical Sciences
Outcome results
None listed